Global To Spell Exaltation For The Gastric Electric Stimulators Market

Posted by Merin John on April 29th, 2021

The global adoption of gastric electric stimulators is projected to witness a surge in demand in 2019, representing a robust year-on-year growth of 6.6 percent, reach a valuation of approximately US$ 188.4 Million, during the same period. Persistence Market Research (PMR) has studied the global gastric electric stimulators market for a period of 8 years, 2018–2026, offering critical insights into demand-driving factors, shaping the adoption trajectory.

The demand for gastric electric stimulators is likely to be driven by a host of pacesetters, including increasing minimally invasive procedures, rising reported cases of Gastroparesis, and favorable reimbursement schemes. Growing prevalence of Gastroparesis—a condition characterized by severity of nausea and vomiting and composite quality-of-life (QOL)—has been identified as the most critical demand generating factor, further making gastric electric stimulators the most preferred treatment alternative for such difficult-to-treat diseases.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25954

Company Profiles

Medtronic Plc.

IntraPace Inc.

ReShape Lifesciences, Inc.

Changzhou Ruishen Medical Equipment Co., Ltd

“Enterra system, the most principal medical device used for treating Gastroparesis, globally, is approved by the FDA as a humanitarian use device, considering its applicability is treating or diagnosing a disease or condition affecting less than 4000 individuals a year in the United States.

Moreover, the American College of Gastroenterology (ACG), although conditionally, recommends the use of gastric electric stimulators for patients with chronic, intractable nausea and vomiting due to Gastroparesis. The gastric electric stimulators, such as Enterra, is a battery-operated gastric neurostimulator, which is normally implanted under the skin in the lower abdomen region”, Senior Analyst, PMR

Considering the rareness of Gastroparesis combined with increasing prevalence of gastric-related conditions, investments in research and clinical studies have substantially increased in the recent years.

Studies indicate that gastric electric stimulators have the ability to normalize symptoms, such as BMI, oral nutritional intake, and gastric emptying rates. Moreover, considered as an effective alternative to gastrectomy in patients with end-stage gastric dysfunction, demand for gastric electric stimulators is anticipated to increase 1.6x, through 2026.